{
  "docId": "019de076-3deb-7779-9c43-c38f834a1cfd",
  "docSlug": "60ad9a5894e93b6af8b1b5bddd2d87e3",
  "documentTitle": "Fusion Pharmaceuticals | Investor Presentation Deck | 30 slides",
  "authorId": "fusion-pharmaceuticals",
  "authorName": "Fusion Pharmaceuticals",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 9,
  "pageCount": 30,
  "prevPage": 8,
  "nextPage": 10,
  "slideType": "traction",
  "function": "show_traction",
  "density": "overcrowded",
  "nDataPoints": 6,
  "notes": "Includes a visual case study (Subject #4) showing PET scan response.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-3deb-7779-9c43-c38f834a1cfd/9",
  "deckHref": "/decks/019de076-3deb-7779-9c43-c38f834a1cfd",
  "deckJsonHref": "/decks/019de076-3deb-7779-9c43-c38f834a1cfd.json",
  "deckAnchorHref": "/decks/019de076-3deb-7779-9c43-c38f834a1cfd#slide-9",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.45,
        "x": 0.53,
        "y": 0.0016
      },
      "kind": "callout",
      "text": "Fusion acquired a Phase 2 IND (TATCIST trial) with plan to develop 225Ac-PSMA-I&T as a potential first to market",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "76f6ce34-f254-4b5c-96e0-606ae8aca04f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.4,
        "x": 0.55,
        "y": 0.0037
      },
      "kind": "image",
      "text": "Subject #4 - Complete Response (both by bone and PSMA-PET scans)",
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4b95dbf6-56eb-470d-8309-1b6397483410",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.45,
        "x": 0.53,
        "y": 0.0083
      },
      "kind": "list",
      "text": "More than 300 patients treated with 225Ac-PSMA globally, including ~100 post-177Lu-PSMA",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "49efb27a-3e04-4749-a736-42a6285f7ee7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.45,
        "x": 0.03,
        "y": 0.43
      },
      "kind": "list",
      "text": "Safety results supportive of developability (no observed kidney toxicity, manageable heme tox and xerostomia)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4b1a6cfd-527a-482c-9e1e-24cc07c19bac",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.45,
        "x": 0.03,
        "y": 0.56
      },
      "kind": "list",
      "text": "Creates opportunity to be a best-in-class therapy",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "54ebe46b-bf40-428d-b8f5-b68335574444",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.45,
        "x": 0.03,
        "y": 0.63
      },
      "kind": "list",
      "text": "Actinium supply barriers are preventing large scale studies and commercialization of the potentially superior alpha therapies",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "744ea37d-bffd-4c53-8c62-1e98b7384449",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.45,
        "x": 0.03,
        "y": 0.26
      },
      "kind": "list",
      "text": "Compelling efficacy data: 177Lu-naïve: 63-66% biochemical response rates; Post 177Lu: 28-65% biochemical response rates",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e66f893b-7fd7-4100-a73b-6a8d21a7d143",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.45,
        "x": 0.03,
        "y": 0.17
      },
      "kind": "paragraph",
      "text": "225Ac-PSMA-I&T (FPI-2265) has achieved clinical POC already in mCRPC",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "167eaea8-5113-48bf-9652-75794fc9969e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.6,
        "x": 0.03,
        "y": 0.03
      },
      "kind": "title",
      "text": "FPI-2265: Fusion’s Phase 2 Actinium-PSMA Program",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9cd48793-26fa-48da-b2eb-4ba726896471",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 9,
      "from": 6,
      "beatId": "9874007f-1efc-436d-b378-6ba4b4f62e19",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Solution",
      "beatSlug": "sequoia-pitch-solution",
      "evidence": "The document presents Fusion Pharmaceuticals' innovative TAT approach and its potential to address unmet medical needs",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 9,
      "from": 6,
      "name": "Quick Win Big Bet",
      "slug": "47-quick-win-big-bet",
      "bestFor": "Transformation planning, 100-day plans, resource allocation",
      "matchId": "813974b3-b15c-424a-8d0f-71fe5c945200",
      "evidence": "The document highlights the potential for Fusion Pharmaceuticals' TAT approach to bring first-in-class agents to market",
      "position": 1,
      "objective": "Quick win and big bet on TAT approach",
      "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
      "confidence": 0.7,
      "description": "Separate initiatives into immediate wins and longer-term strategic bets"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}